PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Chest pain med is effective for refractory angina, but adherence problematic

2011-04-04
(Press-News.org) Ranolazine (Ranexa, Gilead) is an effective anti-anginal therapy in patients with refractory angina; however, at one year only 59 percent of patients remained on the drug, according to a scientific poster that will be presented at the American College of Cardiology (ACC) Scientific Sessions in New Orleans, April 1-3.

Patients with refractory angina, who have chronic chest pain but are not candidates for revascularization, have limited therapeutic options and significant limitations in their quality of life, the study authors wrote. Conversely, patients with chronic angina are often candidates for a procedure.

Ranolazine is approved for patients with chronic stable angina but has not been studied in refractory angina. The prospective Ranolazine Refractory Angina Registry Trial was designed to evaluate the safety, tolerability and effectiveness in RA patients.

"Refractory angina is a challenging and increasingly common clinical problem. These patients are often identified as 'no option patients' due to the lack of treatment choices," explained the study's senior author Timothy D. Henry, MD, interventional cardiologist at Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis.

In order to assess ranolazine for this patient population, the researchers enrolled 100 consecutive patients with class 3 or class 4 angina who were not candidates for revascularization.

The drug was found to be effective in more than 80 percent of patients, but at one year, only 59 percent of the patients remained on ranolazine. Of those remaining on ranolazine, 56 percent had at least a two class improvement in angina.

In the 41 patients who discontinued ranolazine usage, the reasons included: side effects which ranged from lightheadedness, numbness, tingling and constipation (15 patients); major adverse cardiac events, including heart attack (seven patients) or death (two patients); cost (five patients); ineffective (six patients); cost and ineffective (three patients); and for unknown reasons (two patients).

Henry said an approximate 40 percent discontinuation rate is fairly congruent with other medication discontinuation rates, such as statins and antiplatelet therapies. "In challenging economic times, cost is unfortunately going to play a larger role in the medication adherence," he said. "In this study, cost resulted in almost 10 percent of these patients to stop taking the medication." According to the American Academy of Family Physicians, a regimen of 500 mg orally twice-daily ranolazine costs approximately $206 a month.

Also, hospitalization due to angina was similar in the group that discontinued the medication and those patients that remained on ranolazine (32.5 percent versus 32.8 percent, respectively). "The high rate of hospitalization was not surprising but it was disappointing that an effective anti-anginal medication did not decrease the hospitalization rate," Henry said.

"Overall, we found that ranolazine is about 85 percent effective," Henry said. "These findings indicate that ranolazine is a reasonable choice for refractory angina, but it also demonstrates how difficult it can be to treat refractory angina."

### The study was funded by the Minneapolis Heart Institute Foundation, in addition to a research grant from CV Therapeutics, the original developer of ranolazine, which was later purchased by Gilead.

Minneapolis Heart Institute® The Minneapolis Heart Institute® is recognized internationally as one of the world's leading providers of heart and vascular care. This state-of-the-art facility combines the finest in personalized patient care with sophisticated technology in a unique, family-oriented environment. The Institute's programs, a number of which are conducted in conjunction with Abbott Northwestern Hospital, address the full range of heart and vascular health needs: prevention, diagnosis, treatment and rehabilitation.

Minneapolis Heart Institute Foundation The Minneapolis Heart Institute Foundation is dedicated to creating a world without heart disease through groundbreaking clinical research and innovative education programs. MHIF's mission is to promote and improve cardiovascular health, quality of life and longevity for all.


ELSE PRESS RELEASES FROM THIS DATE:

Hartford Students Receive a $78,000 Gift of Success - The Birch Group, LLC and TTI Performance Systems Donate Their Skills and Talent to the Academy

Hartford Students Receive a $78,000 Gift of Success - The Birch Group, LLC and TTI Performance Systems Donate Their Skills and Talent to the Academy
2011-04-04
Each of the 400 students at Hartford Public High School Engineering and Green Technology Academy received a key to success in the form a DISC Behavioral and Workplace Motivator Assessment courtesy of Bill Bonnstetter, CEO and founder of TTI Performance Systems, Ltd. in Scottsdale, AZ and John Birch, founder and president of The Birch Group, LLC, a management consultant firm based in New Britain, CT. TTI Performance Systems generously provided the assessments and The Birch Group administered and coordinated the reports as well as provided training to the students. The value ...

Protocol-driven heart attack care proves effective and contagious

2011-04-04
The implementation of acute heart attack or ST-elevation myocardial infarction (STEMI) guidelines, protocols and standing orders in Minnesota community hospitals without cardiac catheterization labs has dramatically improved since 2003, according to a scientific poster that will be presented at the American College of Cardiology (ACC) Scientific Sessions in New Orleans, April 1-3. Since the 1990s, the American College Cardiology (ACC)/American Heart Association (AHA) STEMI guidelines recommended that all hospitals develop protocols and standing orders (reperfusion strategy, ...

Serum test could identify lung cancer in people who never smoked

2011-04-04
ORLANDO, Fla. — A panel of biomarkers appears to be able to identify the presence of lung cancer in the blood samples of people who have never smoked, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6. While lung cancer has long been linked to smoking, approximately one-fourth of patients with lung cancer have never smoked. Researchers are working on ways to identify the presence of lung cancer in these patients. Charlie Birse, Ph.D., associate director of product development at Celera Corporation, and colleagues are investigating ...

Protein test detects early-stage, asbestos-related pulmonary cancer

2011-04-04
ORLANDO, Fla. — Researchers investigating a novel biomarker test believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. Study results of this aptamer proteomic technology were presented at the AACR 102nd Annual Meeting 2011, held April 2-6. In a blinded test performed under the auspices of the National Cancer Institute's Early Detection Research Network Biomarker Discovery Lab, the proteomic assay could detect 15 of 19 cases of malignant pleural mesothelioma that were in stage 1 or stage 2, making the test about ...

Breast milk may provide a personalized screen of breast cancer risk

2011-04-04
ORLANDO, Fla. — Breast cancer risk can be assessed by examining the epithelial cells found in breast milk, according to preliminary study results presented at the AACR 102nd Annual Meeting 2011, held April 2-6. This screening method has the potential to provide a personalized assessment of breast cancer risk, said lead researcher Kathleen F. Arcaro, Ph.D., associate professor of veterinary and animal sciences at the University of Massachusetts Amherst. Given that roughly 80 percent of women give birth, this screen would also cover a large percentage of the female population. ...

Nicotine does not promote lung cancer growth in mouse models

2011-04-04
ORLANDO, Fla. — Nicotine at doses similar to those found in most nicotine replacements therapies did not increase lung cancer tumor incidence, frequency or size, according to results of a mouse study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6. "If you take our data and combine it with epidemiological data from Europe, even in people who quit smoking and maintain the use of nicotine replacement therapy for months or years, there does not appear to be increased lung cancer incidence," said Phillip A. Dennis, M.D., Ph.D., senior investigator at ...

Aspirin may lower the risk of pancreatic cancer

2011-04-04
ORLANDO, Fla. — The use of aspirin at least once per month is associated with a significant decrease in pancreatic cancer risk, according to results of a large case-control study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6. Xiang-Lin Tan, Ph.D., M.D., a research fellow at Mayo Clinic in Rochester, Minn., said the findings from this large collaborative study are preliminary and do not encourage widespread use of aspirin for this purpose. "The results are not meant to suggest everyone should start taking aspirin once monthly to reduce their risk ...

Lung cancer risk rises in the presence of HPV antibodies

2011-04-04
ORLANDO, Fla. — Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer. Devasena Anantharaman, Ph.D., postdoctoral fellow in the Genetic Epidemiology Group at the IARC in Lyon, France, and ...

MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men

2011-04-04
ORLANDO, FL (April 4, 2011) – Prostate cancer is the second leading cause of cancer-related death among American men. Yet population-wide screening programs have not reduced the number of deaths from the disease. By focusing screening programs on the men who are at greatest risk for aggressive disease or diagnosis at a young age, researchers think they could improve mortality rates and personalize the screening approach. For that reason, scientists have been looking for genetic markers to help them identify exactly which men are at high risk and require regular screening. ...

ThinkHR Joins Assurex Global as Strategic Provider

2011-04-04
ThinkHR, a leading provider of sophisticated, on-demand, Human Resources consulting services through brokers to employers, today announced a Strategic Provider alliance with Assurex Global. The alliance agreement formalizes the independent relationships which currently exist between ThinkHR and a number of Assurex Global Partner firms and further expands ThinkHR's presence and expertise within the Assurex Global network in the United States. ThinkHR's services include HR Hotline (a phone-based HR support service staffed by live, senior-level, human resources professionals), ...

LAST 30 PRESS RELEASES:

University of Oklahoma researcher awarded funding to bridge gap between molecular data and tissue architecture

Nationally-recognized pathologist Paul N. Staats, MD, named Chair of Pathology at University of Maryland School of Medicine

The world’s snow leopards are very similar genetically. That doesn’t bode well for their future

Researchers find key to stopping deadly infection

Leafcutter ants have blind spots, just like truck drivers

Tayac receives funding for community engagement project

Parker receives funding for Elementary Education Program Professional Development School (PDS)

Physicists uncork a message in a bottle from another star

Sanders receives funding for project aimed at enabling prostheses for children with lower extremity amputation

Engineers develop solid lubricant to replace toxic materials in farming

Repurposing gemstone polishing waste to create smart cement

Patient-physician messaging by race, ethnicity, insurance type, and preferred language

Unrecognized motor difficulties and developmental coordination disorder in preschool children

Background genetic variants influence clinical features in complex disorders

Smarter battery tech knows whether your EV will make it home

Overactive microRNAs block fat cell development in progeria

Crosswalk confusion: MA drivers flummoxed by pedestrian hybrid beacons, find UMass Amherst researchers

Study shows heart disease mortality disproportionately burdens low-income communities in California

Intracardiac echocardiography recognized as ‘transformative’ imaging modality in new SCAI position statement

Study finds ‘man’s best friend’ slows cellular aging in female veterans

To get representative health data, researchers hand out fitbits

Hiring in high-growth firms: new study explores the timing of organizational changes

Boosting work engagement through a simple smartphone diary

Climate change may create ‘ecological trap’ for species who can’t adapt

Scientists create ChatGPT-like AI model for neuroscience to build one of the most detailed mouse brain maps to date

AI and omics unlock personalized drugs and RNA therapies for heart disease

2023 ocean heatwave ‘unprecedented but not unexpected’

Johns Hopkins researchers develop AI to predict risk of US car crashes

New drug combination offers hope for men with advanced prostate cancer

New discovery finds gene converts insulin-producing cells into blood-sugar boosters

[Press-News.org] Chest pain med is effective for refractory angina, but adherence problematic